+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)
Hunter Syndrome Treatment Market by Treatment Type, Route Of Administration, Patient Age Group, End User - Global Forecast to 2030- Product Image
Hunter Syndrome Treatment Market by Treatment Type, Route Of Administration, Patient Age Group, End User - Global Forecast to 2030- Product Image
Sale

Hunter Syndrome Treatment Market by Treatment Type, Route Of Administration, Patient Age Group, End User - Global Forecast to 2030

  • PDF Icon

    Report

  • 184 Pages
  • May 2025
  • Region: Global
  • 360iResearch™
  • ID: 5532898
UP TO OFF until Dec 31st 2025
1h Free Analyst Time
Description Jump to:
1h Free Analyst Time

Speak directly to the analyst to clarify any post sales queries you may have.
The Hunter Syndrome Treatment Market grew from USD 1.17 billion in 2024 to USD 1.27 billion in 2025. It is expected to continue growing at a CAGR of 8.15%, reaching USD 1.88 billion by 2030.

A New Era in Hunter Syndrome Management

The landscape of Hunter syndrome treatment has evolved dramatically from its early days of limited therapeutic options to a burgeoning arena of innovation and hope. Historically, patients faced a dire prognosis marked by progressive neurological decline, but recent advances in biotechnology and clinical research have shifted the paradigm. Stakeholders across the healthcare continuum now recognize that a multi-pronged approach-combining targeted enzyme therapies, emerging gene-based interventions, and patient-centric supportive care-offers the best path forward.

Today’s environment demands both an appreciation for the complex biology of mucopolysaccharidosis II and an agile strategy that responds to regulatory shifts, pricing pressures, and patient needs. As payers re-evaluate reimbursement frameworks, and as manufacturing processes mature, industry leaders must adapt their approaches to remain at the forefront of delivering life-changing therapies. This executive summary lays the foundation for understanding the forces redefining treatment pathways and highlights critical considerations for informed decision-making.

Emerging Therapies Reshaping the Treatment Journey

In recent years, the treatment paradigm for Hunter syndrome has undergone transformative shifts driven by breakthroughs in genetic understanding and biopharmaceutical innovation. First, the maturation of adeno associated virus vectors and lentiviral vector platforms has accelerated gene therapy programs, giving rise to clinical studies that aim not just to manage symptoms but to correct the underlying genetic defect. At the same time, refinements in enzyme replacement formulations, including the introduction of second-generation recombinant proteins, have improved tolerability and biodistribution profiles, enabling more consistent systemic delivery.

Beyond molecular advances, the field has embraced a holistic model that places patient quality of life at the center. Digital health solutions now support remote monitoring of respiratory function and mobility, while integrated care networks facilitate timely nutritional and physical therapy interventions. This shift toward personalized and data-driven treatment approaches underscores a broader trend: the convergence of technological innovation and multidisciplinary collaboration to enhance clinical outcomes and patient experiences.

Impact of 2025 US Tariff Changes on Treatment Accessibility

The implementation of new tariff structures in 2025 has introduced fresh challenges and opportunities for stakeholders in the United States. As import duties on critical biologics and vector-based products increase, manufacturers and distributors must reassess supply chain configurations to prevent cost overruns. These changes have prompted some therapy developers to localize manufacturing or explore contract fill-finish partnerships within domestic facilities, thereby mitigating exposure to cross-border fees.

At the same time, payers are scrutinizing total cost of care more closely, balancing the higher upfront investment of advanced therapies against potential long-term savings from reduced hospitalization and supportive care needs. Consequently, value-based contracting models are gaining traction, encouraging manufacturers to demonstrate real-world effectiveness data. In parallel, policy advocates are engaging federal and state authorities to refine tariff harmonization measures, ensuring that patient access remains at the forefront of trade discussions.

In-Depth Treatment, Administration, Age, and Care Setting Perspectives

A nuanced view of the Hunter syndrome market requires a deep dive into treatment type, route of administration, patient demographics, and care settings. Enzyme replacement therapy, anchored by idursulfase and idursulfase beta, continues to represent a cornerstone of clinical management, while the emergence of adeno associated virus vector and lentiviral vector gene therapies has captured the attention of innovators and investors alike. Hematopoietic stem cell transplant options, whether allogeneic or autologous, offer an alternative pathway for a subset of patients, and a robust supportive care framework-spanning nutritional support, pain management, physical therapy, and respiratory support-remains essential to holistic disease management.

Routes of administration also shape patient adherence and resource allocation. Intravenous infusions account for the majority of enzyme application, yet oral formulations are under exploration to broaden patient choice and reduce treatment burden. Subcutaneous delivery presents another promising route, offering potential for home-based administration. Age stratification reveals distinct considerations: middle aged, senior, and young adult patients often present with comorbidities and established treatment regimens, whereas pediatric subgroups encompassing adolescents, children, infants, and toddlers demand carefully tailored dosing strategies and developmental assessments. Finally, the selection of end user sites-from ambulatory surgical centers and home infusion programs to hospital wards and specialty clinics-influences care coordination, reimbursement pathways, and patient satisfaction.

Regional Dynamics Shaping Market Opportunities

Geographic regions exhibit unique regulatory landscapes, reimbursement frameworks, and market maturity trajectories that influence therapeutic adoption and innovation. In the Americas, a combination of dedicated research funding and streamlined regulatory pathways has fostered rapid clinical development, yet insurers continue to challenge high-cost therapies against budgetary constraints. Across Europe, Middle East & Africa, divergent pricing policies and heterogeneous healthcare systems require manufacturers to calibrate market entry strategies, often negotiating country-by-country to secure favorable access conditions. Meanwhile, Asia-Pacific markets offer both the appeal of emerging patient populations and the complexity of variable intellectual property protections, prompting collaborations between global pharmaceutical leaders and regional contract developers.

These regional insights underscore the necessity for agile market access planning, robust stakeholder engagement, and an in-depth understanding of local payer expectations and clinical network structures. By aligning launch strategies with regional priorities-whether through early access programs, adaptive pathways, or risk-sharing agreements-companies can better navigate the evolving global terrain.

Competitive Landscape and Strategic Collaborations Driving Innovation

The competitive landscape for Hunter syndrome therapies is characterized by dynamic innovation and strategic collaborations. Established orphan drug leaders have refined enzyme replacement platforms, while agile biotech firms are pioneering next-generation gene therapies. In parallel, alliances between academic research centers and commercial developers are accelerating translational research, leveraging novel vector technologies and gene editing tools. Recent partnerships have also focused on expanding manufacturing capacity through modular bioprocessing units, ensuring scalability as clinical programs advance into late-stage trials.

Moreover, strategic acquisitions and licensing agreements are reshaping portfolio composition, enabling companies to diversify their pipelines with complementary modalities. These shifts reflect a broader strategic imperative: to integrate cutting-edge science with robust commercial infrastructures, thereby bringing transformative treatments to patients faster and at scale.

Strategic Imperatives for Advancing Therapeutic Outcomes

Industry leaders must adopt several strategic imperatives to maintain momentum in the Hunter syndrome arena. First, investing in platform technologies that support both gene therapy modalities and optimized enzyme replacement constructs will create a versatile pipeline capable of addressing heterogeneous patient needs. Second, forging partnerships with contract manufacturing and clinical research organizations can de-risk capacity constraints and accelerate trial enrollment. Third, embedding real-world evidence generation into post-launch plans will strengthen value propositions with payers and inform adaptive reimbursement agreements.

In addition, prioritizing patient and caregiver engagement through digital support tools, educational resources, and multidisciplinary care networks will enhance adherence and outcomes. Finally, proactive engagement with regulatory authorities to align on accelerated approval pathways and post-approval monitoring frameworks will facilitate smoother market entry and sustained access.

Rigorous Methodology Ensuring Data Integrity and Insights

This report draws on a rigorous methodology that combines primary and secondary research, ensuring a robust evidence base for all insights and recommendations. In-depth interviews with clinical experts, payers, patient advocates, and industry executives were conducted to validate key trends and assess market dynamics from multiple perspectives. Secondary sources included peer-reviewed publications, regulatory filings, clinical trial registries, and proprietary databases, all subjected to meticulous cross-verification to eliminate bias and ensure accuracy.

Quantitative data were analyzed using statistical techniques to identify correlations between therapeutic innovations and patient outcomes, while qualitative inputs were synthesized through thematic analysis. Rigorous quality assurance protocols, including peer reviews and editorial oversight, guarantee that the findings presented here accurately reflect the current state of the Hunter syndrome treatment landscape.

Synthesizing Insights to Navigate Uncertainties and Opportunities

The convergence of novel gene therapies, optimized enzyme replacement protocols, and a patient-centered care ecosystem presents a unique moment of opportunity in Hunter syndrome management. By understanding the implications of tariff policies, regional market nuances, and competitive strategies, stakeholders can navigate the complexities of market access and commercialization with greater confidence. The segmentation insights underscore the need for tailored approaches across treatment types, administration routes, age cohorts, and care settings. These layers of differentiation not only inform clinical development priorities but also guide payer negotiations and patient support initiatives.

As the field continues to advance, collaboration among biopharmaceutical innovators, healthcare providers, and policy makers will remain essential. Together, they can drive sustainable strategies that balance therapeutic innovation with economic realities, ultimately transforming the outlook for patients living with this challenging disorder.

Market Segmentation & Coverage

This research report categorizes to forecast the revenues and analyze trends in each of the following sub-segmentations:
  • Treatment Type
    • Enzyme Replacement Therapy
      • Idursulfase
      • Idursulfase Beta
    • Gene Therapy
      • Adeno Associated Virus Vector
      • Lentiviral Vector
    • Hematopoietic Stem Cell Transplant
      • Allogeneic Transplant
      • Autologous Transplant
    • Supportive Therapy
      • Nutritional Support
      • Pain Management
      • Physical Therapy
      • Respiratory Support
  • Route Of Administration
    • Intravenous
    • Oral
    • Subcutaneous
  • Patient Age Group
    • Adult
      • Middle Aged
      • Senior
      • Young Adult
    • Pediatric
      • Adolescent
      • Child
      • Infant
      • Toddler
  • End User
    • Ambulatory Surgical Center
    • Home Infusion
    • Hospital
    • Specialty Clinic
This research report categorizes to forecast the revenues and analyze trends in each of the following sub-regions:
  • Americas
    • United States
      • California
      • Texas
      • New York
      • Florida
      • Illinois
      • Pennsylvania
      • Ohio
    • Canada
    • Mexico
    • Brazil
    • Argentina
  • Europe, Middle East & Africa
    • United Kingdom
    • Germany
    • France
    • Russia
    • Italy
    • Spain
    • United Arab Emirates
    • Saudi Arabia
    • South Africa
    • Denmark
    • Netherlands
    • Qatar
    • Finland
    • Sweden
    • Nigeria
    • Egypt
    • Turkey
    • Israel
    • Norway
    • Poland
    • Switzerland
  • Asia-Pacific
    • China
    • India
    • Japan
    • Australia
    • South Korea
    • Indonesia
    • Thailand
    • Philippines
    • Malaysia
    • Singapore
    • Vietnam
    • Taiwan
This research report categorizes to delves into recent significant developments and analyze trends in each of the following companies:
  • Takeda Pharmaceutical Company Limited
  • Green Cross Corporation
  • Sanofi
  • JCR Pharmaceuticals
  • GC Pharma
  • Regenxbio
  • Denali Therapeutics

 

Additional Product Information:

  • Purchase of this report includes 1 year online access with quarterly updates.
  • This report can be updated on request. Please contact our Customer Experience team using the Ask a Question widget on our website.

Table of Contents

1. Preface
1.1. Objectives of the Study
1.2. Market Segmentation & Coverage
1.3. Years Considered for the Study
1.4. Currency & Pricing
1.5. Language
1.6. Stakeholders
2. Research Methodology
2.1. Define: Research Objective
2.2. Determine: Research Design
2.3. Prepare: Research Instrument
2.4. Collect: Data Source
2.5. Analyze: Data Interpretation
2.6. Formulate: Data Verification
2.7. Publish: Research Report
2.8. Repeat: Report Update
3. Executive Summary
4. Market Overview
4.1. Introduction
4.2. Market Sizing & Forecasting
5. Market Dynamics
6. Market Insights
6.1. Porter’s Five Forces Analysis
6.2. PESTLE Analysis
7. Cumulative Impact of United States Tariffs 2025
8. Hunter Syndrome Treatment Market, by Treatment Type
8.1. Introduction
8.2. Enzyme Replacement Therapy
8.2.1. Idursulfase
8.2.2. Idursulfase Beta
8.3. Gene Therapy
8.3.1. Adeno Associated Virus Vector
8.3.2. Lentiviral Vector
8.4. Hematopoietic Stem Cell Transplant
8.4.1. Allogeneic Transplant
8.4.2. Autologous Transplant
8.5. Supportive Therapy
8.5.1. Nutritional Support
8.5.2. Pain Management
8.5.3. Physical Therapy
8.5.4. Respiratory Support
9. Hunter Syndrome Treatment Market, by Route Of Administration
9.1. Introduction
9.2. Intravenous
9.3. Oral
9.4. Subcutaneous
10. Hunter Syndrome Treatment Market, by Patient Age Group
10.1. Introduction
10.2. Adult
10.2.1. Middle Aged
10.2.2. Senior
10.2.3. Young Adult
10.3. Pediatric
10.3.1. Adolescent
10.3.2. Child
10.3.3. Infant
10.3.4. Toddler
11. Hunter Syndrome Treatment Market, by End User
11.1. Introduction
11.2. Ambulatory Surgical Center
11.3. Home Infusion
11.4. Hospital
11.5. Specialty Clinic
12. Americas Hunter Syndrome Treatment Market
12.1. Introduction
12.2. United States
12.3. Canada
12.4. Mexico
12.5. Brazil
12.6. Argentina
13. Europe, Middle East & Africa Hunter Syndrome Treatment Market
13.1. Introduction
13.2. United Kingdom
13.3. Germany
13.4. France
13.5. Russia
13.6. Italy
13.7. Spain
13.8. United Arab Emirates
13.9. Saudi Arabia
13.10. South Africa
13.11. Denmark
13.12. Netherlands
13.13. Qatar
13.14. Finland
13.15. Sweden
13.16. Nigeria
13.17. Egypt
13.18. Turkey
13.19. Israel
13.20. Norway
13.21. Poland
13.22. Switzerland
14. Asia-Pacific Hunter Syndrome Treatment Market
14.1. Introduction
14.2. China
14.3. India
14.4. Japan
14.5. Australia
14.6. South Korea
14.7. Indonesia
14.8. Thailand
14.9. Philippines
14.10. Malaysia
14.11. Singapore
14.12. Vietnam
14.13. Taiwan
15. Competitive Landscape
15.1. Market Share Analysis, 2024
15.2. FPNV Positioning Matrix, 2024
15.3. Competitive Analysis
15.3.1. Takeda Pharmaceutical Company Limited
15.3.2. Green Cross Corporation
15.3.3. Sanofi
15.3.4. JCR Pharmaceuticals
15.3.5. GC Pharma
15.3.6. Regenxbio
15.3.7. Denali Therapeutics
16. ResearchAI
17. ResearchStatistics
18. ResearchContacts
19. ResearchArticles
20. Appendix
List of Figures
FIGURE 1. HUNTER SYNDROME TREATMENT MARKET MULTI-CURRENCY
FIGURE 2. HUNTER SYNDROME TREATMENT MARKET MULTI-LANGUAGE
FIGURE 3. HUNTER SYNDROME TREATMENT MARKET RESEARCH PROCESS
FIGURE 4. GLOBAL HUNTER SYNDROME TREATMENT MARKET SIZE, 2018-2030 (USD MILLION)
FIGURE 5. GLOBAL HUNTER SYNDROME TREATMENT MARKET SIZE, BY REGION, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 6. GLOBAL HUNTER SYNDROME TREATMENT MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 7. GLOBAL HUNTER SYNDROME TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2024 VS 2030 (%)
FIGURE 8. GLOBAL HUNTER SYNDROME TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 9. GLOBAL HUNTER SYNDROME TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2024 VS 2030 (%)
FIGURE 10. GLOBAL HUNTER SYNDROME TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 11. GLOBAL HUNTER SYNDROME TREATMENT MARKET SIZE, BY PATIENT AGE GROUP, 2024 VS 2030 (%)
FIGURE 12. GLOBAL HUNTER SYNDROME TREATMENT MARKET SIZE, BY PATIENT AGE GROUP, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 13. GLOBAL HUNTER SYNDROME TREATMENT MARKET SIZE, BY END USER, 2024 VS 2030 (%)
FIGURE 14. GLOBAL HUNTER SYNDROME TREATMENT MARKET SIZE, BY END USER, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 15. AMERICAS HUNTER SYNDROME TREATMENT MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
FIGURE 16. AMERICAS HUNTER SYNDROME TREATMENT MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 17. UNITED STATES HUNTER SYNDROME TREATMENT MARKET SIZE, BY STATE, 2024 VS 2030 (%)
FIGURE 18. UNITED STATES HUNTER SYNDROME TREATMENT MARKET SIZE, BY STATE, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 19. EUROPE, MIDDLE EAST & AFRICA HUNTER SYNDROME TREATMENT MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
FIGURE 20. EUROPE, MIDDLE EAST & AFRICA HUNTER SYNDROME TREATMENT MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 21. ASIA-PACIFIC HUNTER SYNDROME TREATMENT MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
FIGURE 22. ASIA-PACIFIC HUNTER SYNDROME TREATMENT MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 23. HUNTER SYNDROME TREATMENT MARKET SHARE, BY KEY PLAYER, 2024
FIGURE 24. HUNTER SYNDROME TREATMENT MARKET, FPNV POSITIONING MATRIX, 2024
List of Tables
TABLE 1. HUNTER SYNDROME TREATMENT MARKET SEGMENTATION & COVERAGE
TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2024
TABLE 3. GLOBAL HUNTER SYNDROME TREATMENT MARKET SIZE, 2018-2030 (USD MILLION)
TABLE 4. GLOBAL HUNTER SYNDROME TREATMENT MARKET SIZE, BY REGION, 2018-2030 (USD MILLION)
TABLE 5. GLOBAL HUNTER SYNDROME TREATMENT MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
TABLE 6. GLOBAL HUNTER SYNDROME TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
TABLE 7. GLOBAL HUNTER SYNDROME TREATMENT MARKET SIZE, BY ENZYME REPLACEMENT THERAPY, BY REGION, 2018-2030 (USD MILLION)
TABLE 8. GLOBAL HUNTER SYNDROME TREATMENT MARKET SIZE, BY IDURSULFASE, BY REGION, 2018-2030 (USD MILLION)
TABLE 9. GLOBAL HUNTER SYNDROME TREATMENT MARKET SIZE, BY IDURSULFASE BETA, BY REGION, 2018-2030 (USD MILLION)
TABLE 10. GLOBAL HUNTER SYNDROME TREATMENT MARKET SIZE, BY ENZYME REPLACEMENT THERAPY, 2018-2030 (USD MILLION)
TABLE 11. GLOBAL HUNTER SYNDROME TREATMENT MARKET SIZE, BY GENE THERAPY, BY REGION, 2018-2030 (USD MILLION)
TABLE 12. GLOBAL HUNTER SYNDROME TREATMENT MARKET SIZE, BY ADENO ASSOCIATED VIRUS VECTOR, BY REGION, 2018-2030 (USD MILLION)
TABLE 13. GLOBAL HUNTER SYNDROME TREATMENT MARKET SIZE, BY LENTIVIRAL VECTOR, BY REGION, 2018-2030 (USD MILLION)
TABLE 14. GLOBAL HUNTER SYNDROME TREATMENT MARKET SIZE, BY GENE THERAPY, 2018-2030 (USD MILLION)
TABLE 15. GLOBAL HUNTER SYNDROME TREATMENT MARKET SIZE, BY HEMATOPOIETIC STEM CELL TRANSPLANT, BY REGION, 2018-2030 (USD MILLION)
TABLE 16. GLOBAL HUNTER SYNDROME TREATMENT MARKET SIZE, BY ALLOGENEIC TRANSPLANT, BY REGION, 2018-2030 (USD MILLION)
TABLE 17. GLOBAL HUNTER SYNDROME TREATMENT MARKET SIZE, BY AUTOLOGOUS TRANSPLANT, BY REGION, 2018-2030 (USD MILLION)
TABLE 18. GLOBAL HUNTER SYNDROME TREATMENT MARKET SIZE, BY HEMATOPOIETIC STEM CELL TRANSPLANT, 2018-2030 (USD MILLION)
TABLE 19. GLOBAL HUNTER SYNDROME TREATMENT MARKET SIZE, BY SUPPORTIVE THERAPY, BY REGION, 2018-2030 (USD MILLION)
TABLE 20. GLOBAL HUNTER SYNDROME TREATMENT MARKET SIZE, BY NUTRITIONAL SUPPORT, BY REGION, 2018-2030 (USD MILLION)
TABLE 21. GLOBAL HUNTER SYNDROME TREATMENT MARKET SIZE, BY PAIN MANAGEMENT, BY REGION, 2018-2030 (USD MILLION)
TABLE 22. GLOBAL HUNTER SYNDROME TREATMENT MARKET SIZE, BY PHYSICAL THERAPY, BY REGION, 2018-2030 (USD MILLION)
TABLE 23. GLOBAL HUNTER SYNDROME TREATMENT MARKET SIZE, BY RESPIRATORY SUPPORT, BY REGION, 2018-2030 (USD MILLION)
TABLE 24. GLOBAL HUNTER SYNDROME TREATMENT MARKET SIZE, BY SUPPORTIVE THERAPY, 2018-2030 (USD MILLION)
TABLE 25. GLOBAL HUNTER SYNDROME TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 26. GLOBAL HUNTER SYNDROME TREATMENT MARKET SIZE, BY INTRAVENOUS, BY REGION, 2018-2030 (USD MILLION)
TABLE 27. GLOBAL HUNTER SYNDROME TREATMENT MARKET SIZE, BY ORAL, BY REGION, 2018-2030 (USD MILLION)
TABLE 28. GLOBAL HUNTER SYNDROME TREATMENT MARKET SIZE, BY SUBCUTANEOUS, BY REGION, 2018-2030 (USD MILLION)
TABLE 29. GLOBAL HUNTER SYNDROME TREATMENT MARKET SIZE, BY PATIENT AGE GROUP, 2018-2030 (USD MILLION)
TABLE 30. GLOBAL HUNTER SYNDROME TREATMENT MARKET SIZE, BY ADULT, BY REGION, 2018-2030 (USD MILLION)
TABLE 31. GLOBAL HUNTER SYNDROME TREATMENT MARKET SIZE, BY MIDDLE AGED, BY REGION, 2018-2030 (USD MILLION)
TABLE 32. GLOBAL HUNTER SYNDROME TREATMENT MARKET SIZE, BY SENIOR, BY REGION, 2018-2030 (USD MILLION)
TABLE 33. GLOBAL HUNTER SYNDROME TREATMENT MARKET SIZE, BY YOUNG ADULT, BY REGION, 2018-2030 (USD MILLION)
TABLE 34. GLOBAL HUNTER SYNDROME TREATMENT MARKET SIZE, BY ADULT, 2018-2030 (USD MILLION)
TABLE 35. GLOBAL HUNTER SYNDROME TREATMENT MARKET SIZE, BY PEDIATRIC, BY REGION, 2018-2030 (USD MILLION)
TABLE 36. GLOBAL HUNTER SYNDROME TREATMENT MARKET SIZE, BY ADOLESCENT, BY REGION, 2018-2030 (USD MILLION)
TABLE 37. GLOBAL HUNTER SYNDROME TREATMENT MARKET SIZE, BY CHILD, BY REGION, 2018-2030 (USD MILLION)
TABLE 38. GLOBAL HUNTER SYNDROME TREATMENT MARKET SIZE, BY INFANT, BY REGION, 2018-2030 (USD MILLION)
TABLE 39. GLOBAL HUNTER SYNDROME TREATMENT MARKET SIZE, BY TODDLER, BY REGION, 2018-2030 (USD MILLION)
TABLE 40. GLOBAL HUNTER SYNDROME TREATMENT MARKET SIZE, BY PEDIATRIC, 2018-2030 (USD MILLION)
TABLE 41. GLOBAL HUNTER SYNDROME TREATMENT MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 42. GLOBAL HUNTER SYNDROME TREATMENT MARKET SIZE, BY AMBULATORY SURGICAL CENTER, BY REGION, 2018-2030 (USD MILLION)
TABLE 43. GLOBAL HUNTER SYNDROME TREATMENT MARKET SIZE, BY HOME INFUSION, BY REGION, 2018-2030 (USD MILLION)
TABLE 44. GLOBAL HUNTER SYNDROME TREATMENT MARKET SIZE, BY HOSPITAL, BY REGION, 2018-2030 (USD MILLION)
TABLE 45. GLOBAL HUNTER SYNDROME TREATMENT MARKET SIZE, BY SPECIALTY CLINIC, BY REGION, 2018-2030 (USD MILLION)
TABLE 46. AMERICAS HUNTER SYNDROME TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
TABLE 47. AMERICAS HUNTER SYNDROME TREATMENT MARKET SIZE, BY ENZYME REPLACEMENT THERAPY, 2018-2030 (USD MILLION)
TABLE 48. AMERICAS HUNTER SYNDROME TREATMENT MARKET SIZE, BY GENE THERAPY, 2018-2030 (USD MILLION)
TABLE 49. AMERICAS HUNTER SYNDROME TREATMENT MARKET SIZE, BY HEMATOPOIETIC STEM CELL TRANSPLANT, 2018-2030 (USD MILLION)
TABLE 50. AMERICAS HUNTER SYNDROME TREATMENT MARKET SIZE, BY SUPPORTIVE THERAPY, 2018-2030 (USD MILLION)
TABLE 51. AMERICAS HUNTER SYNDROME TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 52. AMERICAS HUNTER SYNDROME TREATMENT MARKET SIZE, BY PATIENT AGE GROUP, 2018-2030 (USD MILLION)
TABLE 53. AMERICAS HUNTER SYNDROME TREATMENT MARKET SIZE, BY ADULT, 2018-2030 (USD MILLION)
TABLE 54. AMERICAS HUNTER SYNDROME TREATMENT MARKET SIZE, BY PEDIATRIC, 2018-2030 (USD MILLION)
TABLE 55. AMERICAS HUNTER SYNDROME TREATMENT MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 56. AMERICAS HUNTER SYNDROME TREATMENT MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
TABLE 57. UNITED STATES HUNTER SYNDROME TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
TABLE 58. UNITED STATES HUNTER SYNDROME TREATMENT MARKET SIZE, BY ENZYME REPLACEMENT THERAPY, 2018-2030 (USD MILLION)
TABLE 59. UNITED STATES HUNTER SYNDROME TREATMENT MARKET SIZE, BY GENE THERAPY, 2018-2030 (USD MILLION)
TABLE 60. UNITED STATES HUNTER SYNDROME TREATMENT MARKET SIZE, BY HEMATOPOIETIC STEM CELL TRANSPLANT, 2018-2030 (USD MILLION)
TABLE 61. UNITED STATES HUNTER SYNDROME TREATMENT MARKET SIZE, BY SUPPORTIVE THERAPY, 2018-2030 (USD MILLION)
TABLE 62. UNITED STATES HUNTER SYNDROME TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 63. UNITED STATES HUNTER SYNDROME TREATMENT MARKET SIZE, BY PATIENT AGE GROUP, 2018-2030 (USD MILLION)
TABLE 64. UNITED STATES HUNTER SYNDROME TREATMENT MARKET SIZE, BY ADULT, 2018-2030 (USD MILLION)
TABLE 65. UNITED STATES HUNTER SYNDROME TREATMENT MARKET SIZE, BY PEDIATRIC, 2018-2030 (USD MILLION)
TABLE 66. UNITED STATES HUNTER SYNDROME TREATMENT MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 67. UNITED STATES HUNTER SYNDROME TREATMENT MARKET SIZE, BY STATE, 2018-2030 (USD MILLION)
TABLE 68. CANADA HUNTER SYNDROME TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
TABLE 69. CANADA HUNTER SYNDROME TREATMENT MARKET SIZE, BY ENZYME REPLACEMENT THERAPY, 2018-2030 (USD MILLION)
TABLE 70. CANADA HUNTER SYNDROME TREATMENT MARKET SIZE, BY GENE THERAPY, 2018-2030 (USD MILLION)
TABLE 71. CANADA HUNTER SYNDROME TREATMENT MARKET SIZE, BY HEMATOPOIETIC STEM CELL TRANSPLANT, 2018-2030 (USD MILLION)
TABLE 72. CANADA HUNTER SYNDROME TREATMENT MARKET SIZE, BY SUPPORTIVE THERAPY, 2018-2030 (USD MILLION)
TABLE 73. CANADA HUNTER SYNDROME TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 74. CANADA HUNTER SYNDROME TREATMENT MARKET SIZE, BY PATIENT AGE GROUP, 2018-2030 (USD MILLION)
TABLE 75. CANADA HUNTER SYNDROME TREATMENT MARKET SIZE, BY ADULT, 2018-2030 (USD MILLION)
TABLE 76. CANADA HUNTER SYNDROME TREATMENT MARKET SIZE, BY PEDIATRIC, 2018-2030 (USD MILLION)
TABLE 77. CANADA HUNTER SYNDROME TREATMENT MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 78. MEXICO HUNTER SYNDROME TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
TABLE 79. MEXICO HUNTER SYNDROME TREATMENT MARKET SIZE, BY ENZYME REPLACEMENT THERAPY, 2018-2030 (USD MILLION)
TABLE 80. MEXICO HUNTER SYNDROME TREATMENT MARKET SIZE, BY GENE THERAPY, 2018-2030 (USD MILLION)
TABLE 81. MEXICO HUNTER SYNDROME TREATMENT MARKET SIZE, BY HEMATOPOIETIC STEM CELL TRANSPLANT, 2018-2030 (USD MILLION)
TABLE 82. MEXICO HUNTER SYNDROME TREATMENT MARKET SIZE, BY SUPPORTIVE THERAPY, 2018-2030 (USD MILLION)
TABLE 83. MEXICO HUNTER SYNDROME TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 84. MEXICO HUNTER SYNDROME TREATMENT MARKET SIZE, BY PATIENT AGE GROUP, 2018-2030 (USD MILLION)
TABLE 85. MEXICO HUNTER SYNDROME TREATMENT MARKET SIZE, BY ADULT, 2018-2030 (USD MILLION)
TABLE 86. MEXICO HUNTER SYNDROME TREATMENT MARKET SIZE, BY PEDIATRIC, 2018-2030 (USD MILLION)
TABLE 87. MEXICO HUNTER SYNDROME TREATMENT MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 88. BRAZIL HUNTER SYNDROME TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
TABLE 89. BRAZIL HUNTER SYNDROME TREATMENT MARKET SIZE, BY ENZYME REPLACEMENT THERAPY, 2018-2030 (USD MILLION)
TABLE 90. BRAZIL HUNTER SYNDROME TREATMENT MARKET SIZE, BY GENE THERAPY, 2018-2030 (USD MILLION)
TABLE 91. BRAZIL HUNTER SYNDROME TREATMENT MARKET SIZE, BY HEMATOPOIETIC STEM CELL TRANSPLANT, 2018-2030 (USD MILLION)
TABLE 92. BRAZIL HUNTER SYNDROME TREATMENT MARKET SIZE, BY SUPPORTIVE THERAPY, 2018-2030 (USD MILLION)
TABLE 93. BRAZIL HUNTER SYNDROME TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 94. BRAZIL HUNTER SYNDROME TREATMENT MARKET SIZE, BY PATIENT AGE GROUP, 2018-2030 (USD MILLION)
TABLE 95. BRAZIL HUNTER SYNDROME TREATMENT MARKET SIZE, BY ADULT, 2018-2030 (USD MILLION)
TABLE 96. BRAZIL HUNTER SYNDROME TREATMENT MARKET SIZE, BY PEDIATRIC, 2018-2030 (USD MILLION)
TABLE 97. BRAZIL HUNTER SYNDROME TREATMENT MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 98. ARGENTINA HUNTER SYNDROME TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
TABLE 99. ARGENTINA HUNTER SYNDROME TREATMENT MARKET SIZE, BY ENZYME REPLACEMENT THERAPY, 2018-2030 (USD MILLION)
TABLE 100. ARGENTINA HUNTER SYNDROME TREATMENT MARKET SIZE, BY GENE THERAPY, 2018-2030 (USD MILLION)
TABLE 101. ARGENTINA HUNTER SYNDROME TREATMENT MARKET SIZE, BY HEMATOPOIETIC STEM CELL TRANSPLANT, 2018-2030 (USD MILLION)
TABLE 102. ARGENTINA HUNTER SYNDROME TREATMENT MARKET SIZE, BY SUPPORTIVE THERAPY, 2018-2030 (USD MILLION)
TABLE 103. ARGENTINA HUNTER SYNDROME TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 104. ARGENTINA HUNTER SYNDROME TREATMENT MARKET SIZE, BY PATIENT AGE GROUP, 2018-2030 (USD MILLION)
TABLE 105. ARGENTINA HUNTER SYNDROME TREATMENT MARKET SIZE, BY ADULT, 2018-2030 (USD MILLION)
TABLE 106. ARGENTINA HUNTER SYNDROME TREATMENT MARKET SIZE, BY PEDIATRIC, 2018-2030 (USD MILLION)
TABLE 107. ARGENTINA HUNTER SYNDROME TREATMENT MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 108. EUROPE, MIDDLE EAST & AFRICA HUNTER SYNDROME TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
TABLE 109. EUROPE, MIDDLE EAST & AFRICA HUNTER SYNDROME TREATMENT MARKET SIZE, BY ENZYME REPLACEMENT THERAPY, 2018-2030 (USD MILLION)
TABLE 110. EUROPE, MIDDLE EAST & AFRICA HUNTER SYNDROME TREATMENT MARKET SIZE, BY GENE THERAPY, 2018-2030 (USD MILLION)
TABLE 111. EUROPE, MIDDLE EAST & AFRICA HUNTER SYNDROME TREATMENT MARKET SIZE, BY HEMATOPOIETIC STEM CELL TRANSPLANT, 2018-2030 (USD MILLION)
TABLE 112. EUROPE, MIDDLE EAST & AFRICA HUNTER SYNDROME TREATMENT MARKET SIZE, BY SUPPORTIVE THERAPY, 2018-2030 (USD MILLION)
TABLE 113. EUROPE, MIDDLE EAST & AFRICA HUNTER SYNDROME TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 114. EUROPE, MIDDLE EAST & AFRICA HUNTER SYNDROME TREATMENT MARKET SIZE, BY PATIENT AGE GROUP, 2018-2030 (USD MILLION)
TABLE 115. EUROPE, MIDDLE EAST & AFRICA HUNTER SYNDROME TREATMENT MARKET SIZE, BY ADULT, 2018-2030 (USD MILLION)
TABLE 116. EUROPE, MIDDLE EAST & AFRICA HUNTER SYNDROME TREATMENT MARKET SIZE, BY PEDIATRIC, 2018-2030 (USD MILLION)
TABLE 117. EUROPE, MIDDLE EAST & AFRICA HUNTER SYNDROME TREATMENT MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 118. EUROPE, MIDDLE EAST & AFRICA HUNTER SYNDROME TREATMENT MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
TABLE 119. UNITED KINGDOM HUNTER SYNDROME TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
TABLE 120. UNITED KINGDOM HUNTER SYNDROME TREATMENT MARKET SIZE, BY ENZYME REPLACEMENT THERAPY, 2018-2030 (USD MILLION)
TABLE 121. UNITED KINGDOM HUNTER SYNDROME TREATMENT MARKET SIZE, BY GENE THERAPY, 2018-2030 (USD MILLION)
TABLE 122. UNITED KINGDOM HUNTER SYNDROME TREATMENT MARKET SIZE, BY HEMATOPOIETIC STEM CELL TRANSPLANT, 2018-2030 (USD MILLION)
TABLE 123. UNITED KINGDOM HUNTER SYNDROME TREATMENT MARKET SIZE, BY SUPPORTIVE THERAPY, 2018-2030 (USD MILLION)
TABLE 124. UNITED KINGDOM HUNTER SYNDROME TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 125. UNITED KINGDOM HUNTER SYNDROME TREATMENT MARKET SIZE, BY PATIENT AGE GROUP, 2018-2030 (USD MILLION)
TABLE 126. UNITED KINGDOM HUNTER SYNDROME TREATMENT MARKET SIZE, BY ADULT, 2018-2030 (USD MILLION)
TABLE 127. UNITED KINGDOM HUNTER SYNDROME TREATMENT MARKET SIZE, BY PEDIATRIC, 2018-2030 (USD MILLION)
TABLE 128. UNITED KINGDOM HUNTER SYNDROME TREATMENT MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 129. GERMANY HUNTER SYNDROME TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
TABLE 130. GERMANY HUNTER SYNDROME TREATMENT MARKET SIZE, BY ENZYME REPLACEMENT THERAPY, 2018-2030 (USD MILLION)
TABLE 131. GERMANY HUNTER SYNDROME TREATMENT MARKET SIZE, BY GENE THERAPY, 2018-2030 (USD MILLION)
TABLE 132. GERMANY HUNTER SYNDROME TREATMENT MARKET SIZE, BY HEMATOPOIETIC STEM CELL TRANSPLANT, 2018-2030 (USD MILLION)
TABLE 133. GERMANY HUNTER SYNDROME TREATMENT MARKET SIZE, BY SUPPORTIVE THERAPY, 2018-2030 (USD MILLION)
TABLE 134. GERMANY HUNTER SYNDROME TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 135. GERMANY HUNTER SYNDROME TREATMENT MARKET SIZE, BY PATIENT AGE GROUP, 2018-2030 (USD MILLION)
TABLE 136. GERMANY HUNTER SYNDROME TREATMENT MARKET SIZE, BY ADULT, 2018-2030 (USD MILLION)
TABLE 137. GERMANY HUNTER SYNDROME TREATMENT MARKET SIZE, BY PEDIATRIC, 2018-2030 (USD MILLION)
TABLE 138. GERMANY HUNTER SYNDROME TREATMENT MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 139. FRANCE HUNTER SYNDROME TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
TABLE 140. FRANCE HUNTER SYNDROME TREATMENT MARKET SIZE, BY ENZYME REPLACEMENT THERAPY, 2018-2030 (USD MILLION)
TABLE 141. FRANCE HUNTER SYNDROME TREATMENT MARKET SIZE, BY GENE THERAPY, 2018-2030 (USD MILLION)
TABLE 142. FRANCE HUNTER SYNDROME TREATMENT MARKET SIZE, BY HEMATOPOIETIC STEM CELL TRANSPLANT, 2018-2030 (USD MILLION)
TABLE 143. FRANCE HUNTER SYNDROME TREATMENT MARKET SIZE, BY SUPPORTIVE THERAPY, 2018-2030 (USD MILLION)
TABLE 144. FRANCE HUNTER SYNDROME TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 145. FRANCE HUNTER SYNDROME TREATMENT MARKET SIZE, BY PATIENT AGE GROUP, 2018-2030 (USD MILLION)
TABLE 146. FRANCE HUNTER SYNDROME TREATMENT MARKET SIZE, BY ADULT, 2018-2030 (USD MILLION)
TABLE 147. FRANCE HUNTER SYNDROME TREATMENT MARKET SIZE, BY PEDIATRIC, 2018-2030 (USD MILLION)
TABLE 148. FRANCE HUNTER SYNDROME TREATMENT MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 149. RUSSIA HUNTER SYNDROME TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
TABLE 150. RUSSIA HUNTER SYNDROME TREATMENT MARKET SIZE, BY ENZYME REPLACEMENT THERAPY, 2018-2030 (USD MILLION)
TABLE 151. RUSSIA HUNTER SYNDROME TREATMENT MARKET SIZE, BY GENE THERAPY, 2018-2030 (USD MILLION)
TABLE 152. RUSSIA HUNTER SYNDROME TREATMENT MARKET SIZE, BY HEMATOPOIETIC STEM CELL TRANSPLANT, 2018-2030 (USD MILLION)
TABLE 153. RUSSIA HUNTER SYNDROME TREATMENT MARKET SIZE, BY SUPPORTIVE THERAPY, 2018-2030 (USD MILLION)
TABLE 154. RUSSIA HUNTER SYNDROME TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 155. RUSSIA HUNTER SYNDROME TREATMENT MARKET SIZE, BY PATIENT AGE GROUP, 2018-2030 (USD MILLION)
TABLE 156. RUSSIA HUNTER SYNDROME TREATMENT MARKET SIZE, BY ADULT, 2018-2030 (USD MILLION)
TABLE 157. RUSSIA HUNTER SYNDROME TREATMENT MARKET SIZE, BY PEDIATRIC, 2018-2030 (USD MILLION)
TABLE 158. RUSSIA HUNTER SYNDROME TREATMENT MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 159. ITALY HUNTER SYNDROME TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
TABLE 160. ITALY HUNTER SYNDROME TREATMENT MARKET SIZE, BY ENZYME REPLACEMENT THERAPY, 2018-2030 (USD MILLION)
TABLE 161. ITALY HUNTER SYNDROME TREATMENT MARKET SIZE, BY GENE THERAPY, 2018-2030 (USD MILLION)
TABLE 162. ITALY HUNTER SYNDROME TREATMENT MARKET SIZE, BY HEMATOPOIETIC STEM CELL TRANSPLANT, 2018-2030 (USD MILLION)
TABLE 163. ITALY HUNTER SYNDROME TREATMENT MARKET SIZE, BY SUPPORTIVE THERAPY, 2018-2030 (USD MILLION)
TABLE 164. ITALY HUNTER SYNDROME TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 165. ITALY HUNTER SYNDROME TREATMENT MARKET SIZE, BY PATIENT AGE GROUP, 2018-2030 (USD MILLION)
TABLE 166. ITALY HUNTER SYNDROME TREATMENT MARKET SIZE, BY ADULT, 2018-2030 (USD MILLION)
TABLE 167. ITALY HUNTER SYNDROME TREATMENT MARKET SIZE, BY PEDIATRIC, 2018-2030 (USD MILLION)
TABLE 168. ITALY HUNTER SYNDROME TREATMENT MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 169. SPAIN HUNTER SYNDROME TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
TABLE 170. SPAIN HUNTER SYNDROME TREATMENT MARKET SIZE, BY ENZYME REPLACEMENT THERAPY, 2018-2030 (USD MILLION)
TABLE 171. SPAIN HUNTER SYNDROME TREATMENT MARKET SIZE, BY GENE THERAPY, 2018-2030 (USD MILLION)
TABLE 172. SPAIN HUNTER SYNDROME TREATMENT MARKET SIZE, BY HEMATOPOIETIC STEM CELL TRANSPLANT, 2018-2030 (USD MILLION)
TABLE 173. SPAIN HUNTER SYNDROME TREATMENT MARKET SIZE, BY SUPPORTIVE THERAPY, 2018-2030 (USD MILLION)
TABLE 174. SPAIN HUNTER SYNDROME TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 175. SPAIN HUNTER SYNDROME TREATMENT MARKET SIZE, BY PATIENT AGE GROUP, 2018-2030 (USD MILLION)
TABLE 176. SPAIN HUNTER SYNDROME TREATMENT MARKET SIZE, BY ADULT, 2018-2030 (USD MILLION)
TABLE 177. SPAIN HUNTER SYNDROME TREATMENT MARKET SIZE, BY PEDIATRIC, 2018-2030 (USD MILLION)
TABLE 178. SPAIN HUNTER SYNDROME TREATMENT MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 179. UNITED ARAB EMIRATES HUNTER SYNDROME TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
TABLE 180. UNITED ARAB EMIRATES HUNTER SYNDROME TREATMENT MARKET SIZE, BY ENZYME REPLACEMENT THERAPY, 2018-2030 (USD MILLION)
TABLE 181. UNITED ARAB EMIRATES HUNTER SYNDROME TREATMENT MARKET SIZE, BY GENE THERAPY, 2018-2030 (USD MILLION)
TABLE 182. UNITED ARAB EMIRATES HUNTER SYNDROME TREATMENT MARKET SIZE, BY HEMATOPOIETIC STEM CELL TRANSPLANT, 2018-2030 (USD MILLION)
TABLE 183. UNITED ARAB EMIRATES HUNTER SYNDROME TREATMENT MARKET SIZE, BY SUPPORTIVE THERAPY, 2018-2030 (USD MILLION)
TABLE 184. UNITED ARAB EMIRATES HUNTER SYNDROME TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 185. UNITED ARAB EMIRATES HUNTER SYNDROME TREATMENT MARKET SIZE, BY PATIENT AGE GROUP, 2018-2030 (USD MILLION)
TABLE 186. UNITED ARAB EMIRATES HUNTER SYNDROME TREATMENT MARKET SIZE, BY ADULT, 2018-2030 (USD MILLION)
TABLE 187. UNITED ARAB EMIRATES HUNTER SYNDROME TREATMENT MARKET SIZE, BY PEDIATRIC, 2018-2030 (USD MILLION)
TABLE 188. UNITED ARAB EMIRATES HUNTER SYNDROME TREATMENT MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 189. SAUDI ARABIA HUNTER SYNDROME TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
TABLE 190. SAUDI ARABIA HUNTER SYNDROME TREATMENT MARKET SIZE, BY ENZYME REPLACEMENT THERAPY, 2018-2030 (USD MILLION)
TABLE 191. SAUDI ARABIA HUNTER SYNDROME TREATMENT MARKET SIZE, BY GENE THERAPY, 2018-2030 (USD MILLION)
TABLE 192. SAUDI ARABIA HUNTER SYNDROME TREATMENT MARKET SIZE, BY HEMATOPOIETIC STEM CELL TRANSPLANT, 2018-2030 (USD MILLION)
TABLE 193. SAUDI ARABIA HUNTER SYNDROME TREATMENT MARKET SIZE, BY SUPPORTIVE THERAPY, 2018-2030 (USD MILLION)
TABLE 194. SAUDI ARABIA HUNTER SYNDROME TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 195. SAUDI ARABIA HUNTER SYNDROME TREATMENT MARKET SIZE, BY PATIENT AGE GROUP, 2018-2030 (USD MILLION)
TABLE 196. SAUDI ARABIA HUNTER SYNDROME TREATMENT MARKET SIZE, BY ADULT, 2018-2030 (USD MILLION)
TABLE 197. SAUDI ARABIA HUNTER SYNDROME TREATMENT MARKET SIZE, BY PEDIATRIC, 2018-2030 (USD MILLION)
TABLE 198. SAUDI ARABIA HUNTER SYNDROME TREATMENT MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 199. SOUTH AFRICA HUNTER SYNDROME TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
TABLE 200. SOUTH AFRICA HUNTER SYNDROME TREATMENT MARKET SIZE, BY ENZYME REPLACEMENT THERAPY, 2018-2030 (USD MILLION)
TABLE 201. SOUTH AFRICA HUNTER SYNDROME TREATMENT MARKET SIZE, BY GENE THERAPY, 2018-2030 (USD MILLION)
TABLE 202. SOUTH AFRICA HUNTER SYNDROME TREATMENT MARKET SIZE, BY HEMATOPOIETIC STEM CELL TRANSPLANT, 2018-2030 (USD MILLION)
TABLE 203. SOUTH AFRICA HUNTER SYNDROME TREATMENT MARKET SIZE, BY SUPPORTIVE THERAPY, 2018-2030 (USD MILLION)
TABLE 204. SOUTH AFRICA HUNTER SYNDROME TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 205. SOUTH AFRICA HUNTER SYNDROME TREATMENT MARKET SIZE, BY PATIENT AGE GROUP, 2018-2030 (USD MILLION)
TABLE 206. SOUTH AFRICA HUNTER SYNDROME TREATMENT MARKET SIZE, BY ADULT, 2018-2030 (USD MILLION)
TABLE 207. SOUTH AFRICA HUNTER SYNDROME TREATMENT MARKET SIZE, BY PEDIATRIC, 2018-2030 (USD MILLION)
TABLE 208. SOUTH AFRICA HUNTER SYNDROME TREATMENT MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 209. DENMARK HUNTER SYNDROME TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
TABLE 210. DENMARK HUNTER SYNDROME TREATMENT MARKET SIZE, BY ENZYME REPLACEMENT THERAPY, 2018-2030 (USD MILLION)
TABLE 211. DENMARK HUNTER SYNDROME TREATMENT MARKET SIZE, BY GENE THERAPY, 2018-2030 (USD MILLION)
TABLE 212. DENMARK HUNTER SYNDROME TREATMENT MARKET SIZE, BY HEMATOPOIETIC STEM CELL TRANSPLANT, 2018-2030 (USD MILLION)
TABLE 213. DENMARK HUNTER SYNDROME TREATMENT MARKET SIZE, BY SUPPORTIVE THERAPY, 2018-2030 (USD MILLION)
TABLE 214. DENMARK HUNTER SYNDROME TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 215. DENMARK HUNTER SYNDROME TREATMENT MARKET SIZE, BY PATIENT AGE GROUP, 2018-2030 (USD MILLION)
TABLE 216. DENMARK HUNTER SYNDROME TREATMENT MARKET SIZE, BY ADULT, 2018-2030 (USD MILLION)
TABLE 217. DENMARK HUNTER SYNDROME TREATMENT MARKET SIZE, BY PEDIATRIC, 2018-2030 (USD MILLION)
TABLE 218. DENMARK HUNTER SYNDROME TREATMENT MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 219. NETHERLANDS HUNTER SYNDROME TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
TABLE 220. NETHERLANDS HUNTER SYNDROME TREATMENT MARKET SIZE, BY ENZYME REPLACEMENT THERAPY, 2018-2030 (USD MILLION)
TABLE 221. NETHERLANDS HUNTER SYNDROME TREATMENT MARKET SIZE, BY GENE THERAPY, 2018-2030 (USD MILLION)
TABLE 222. NETHERLANDS HUNTER SYNDROME TREATMENT MARKET SIZE, BY HEMATOPOIETIC STEM CELL TRANSPLANT, 2018-2030 (USD MILLION)
TABLE 223. NETHERLANDS HUNTER SYNDROME TREATMENT MARKET SIZE, BY SUPPORTIVE THERAPY, 2018-2030 (USD MILLION)
TABLE 224. NETHERLANDS HUNTER SYNDROME TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 225. NETHERLANDS HUNTER SYNDROME TREATMENT MARKET SIZE, BY PATIENT AGE GROUP, 2018-2030 (USD MILLION)
TABLE 226. NETHERLANDS HUNTER SYNDROME TREATMENT MARKET SIZE, BY ADULT, 2018-2030 (USD MILLION)
TABLE 227. NETHERLANDS HUNTER SYNDROME TREATMENT MARKET SIZE, BY PEDIATRIC, 2018-2030 (USD MILLION)
TABLE 228. NETHERLANDS HUNTER SYNDROME TREATMENT MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 229. QATAR HUNTER SYNDROME TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
TABLE 230. QATAR HUNTER SYNDROME TREATMENT MARKET SIZE, BY ENZYME REPLACEMENT THERAPY, 2018-2030 (USD MILLION)
TABLE 231. QATAR HUNTER SYNDROME TREATMENT MARKET SIZE, BY GENE THERAPY, 2018-2030 (USD MILLION)
TABLE 232. QATAR HUNTER SYNDROME TREATMENT MARKET SIZE, BY HEMATOPOIETIC STEM CELL TRANSPLANT, 2018-2030 (USD MILLION)
TABLE 233. QATAR HUNTER SYNDROME TREATMENT MARKET SIZE, BY SUPPORTIVE THERAPY, 2018-2030 (USD MILLION)
TABLE 234. QATAR HUNTER SYNDROME TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 235. QATAR HUNTER SYNDROME TREATMENT MARKET SIZE, BY PATIENT AGE GROUP, 2018-2030 (USD MILLION)
TABLE 236. QATAR HUNTER SYNDROME TREATMENT MARKET SIZE, BY ADULT, 2018-2030 (USD MILLION)
TABLE 237. QATAR HUNTER SYNDROME TREATMENT MARKET SIZE, BY PEDIATRIC, 2018-2030 (USD MILLION)
TABLE 238. QATAR HUNTER SYNDROME TREATMENT MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 239. FINLAND HUNTER SYNDROME TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
TABLE 240. FINLAND HUNTER SYNDROME TREATMENT MARKET SIZE, BY ENZYME REPLACEMENT THERAPY, 2018-2030 (USD MILLION)
TABLE 241. FINLAND HUNTER SYNDROME TREATMENT MARKET SIZE, BY GENE THERAPY, 2018-2030 (USD MILLION)
TABLE 242. FINLAND HUNTER SYNDROME TREATMENT MARKET SIZE, BY HEMATOPOIETIC STEM CELL TRANSPLANT, 2018-2030 (USD MILLION)
TABLE 243. FINLAND HUNTER SYNDROME TREATMENT MARKET SIZE, BY SUPPORTIVE THERAPY, 2018-2030 (USD MILLION)
TABLE 244. FINLAND HUNTER SYNDROME TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 245. FINLAND HUNTER SYNDROME TREATMENT MARKET SIZE, BY PATIENT AGE GROUP, 2018-2030 (USD MILLION)
TABLE 246. FINLAND HUNTER SYNDROME TREATMENT MARKET SIZE, BY ADULT, 2018-2030 (USD MILLION)
TABLE 247. FINLAND HUNTER SYNDROME TREATMENT MARKET SIZE, BY PEDIATRIC, 2018-2030 (USD MILLION)
TABLE 248. FINLAND HUNTER SYNDROME TREATMENT MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 249. SWEDEN HUNTER SYNDROME TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
TABLE 250. SWEDEN HUNTER SYNDROME TREATMENT MARKET SIZE, BY ENZYME REPLACEMENT THERAPY, 2018-2030 (USD MILLION)
TABLE 251. SWEDEN HUNTER SYNDROME TREATMENT MARKET SIZE, BY GENE THERAPY, 2018-2030 (USD MILLION)
TABLE 252. SWEDEN HUNTER SYNDROME TREATMENT MARKET SIZE, BY HEMATOPOIETIC STEM CELL TRANSPLANT, 2018-2030 (USD MILLION)
TABLE 253. SWEDEN HUNTER SYNDROME TREATMENT MARKET SIZE, BY SUPPORTIVE THERAPY, 2018-2030 (USD MILLION)
TABLE 254. SWEDEN HUNTER SYNDROME TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 255. SWEDEN HUNTER SYNDROME TREATMENT MARKET SIZE, BY PATIENT AGE GROUP, 2018-2030 (USD MILLION)
TABLE 256. SWEDEN HUNTER SYNDROME TREATMENT MARKET SIZE, BY ADULT, 2018-2030 (USD MILLION)
TABLE 257. SWEDEN HUNTER SYNDROME TREATMENT MARKET SIZE, BY PEDIATRIC, 2018-2030 (USD MILLION)
TABLE 258. SWEDEN HUNTER SYNDROME TREATMENT MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 259. NIGERIA HUNTER SYNDROME TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
TABLE 260. NIGERIA HUNTER SYNDROME TREATMENT MARKET SIZE, BY ENZYME REPLACEMENT THERAPY, 2018-2030 (USD MILLION)
TABLE 261. NIGERIA HUNTER SYNDROME TREATMENT MARKET SIZE, BY GENE THERAPY, 2018-2030 (USD MILLION)
TABLE 262. NIGERIA HUNTER SYNDROME TREATMENT MARKET SIZE, BY HEMATOPOIETIC STEM CELL TRANSPLANT, 2018-2030 (USD MILLION)
TABLE 263. NIGERIA HUNTER SYNDROME TREATMENT MARKET SIZE, BY SUPPORTIVE THERAPY, 2018-2030 (USD MILLION)
TABLE 264. NIGERIA HUNTER SYNDROME TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 265. NIGERIA HUNTER SYNDROME TREATMENT MARKET SIZE, BY PATIENT AGE GROUP, 2018-2030 (USD MILLION)
TABLE 266. NIGERIA HUNTER SYNDROME TREATMENT MARKET SIZE, BY ADULT, 2018-2030 (USD MILLION)
TABLE 267. NIGERIA HUNTER SYNDROME TREATMENT MARKET SIZE, BY PEDIATRIC, 2018-2030 (USD MILLION)
TABLE 268. NIGERIA HUNTER SYNDROME TREATMENT MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 269. EGYPT HUNTER SYNDROME TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
TABLE 270. EGYPT HUNTER SYNDROME TREATMENT MARKET SIZE, BY ENZYME REPLACEMENT THERAPY, 2018-2030 (USD MILLION)
TABLE 271. EGYPT HUNTER SYNDROME TREATMENT MARKET SIZE, BY GENE THERAPY, 2018-2030 (USD MILLION)
TABLE 272. EGYPT HUNTER SYNDROME TREATMENT MARKET SIZE, BY HEMATOPOIETIC STEM CELL TRANSPLANT, 2018-2030 (USD MILLION)
TABLE 273. EGYPT HUNTER SYNDROME TREATMENT MARKET SIZE, BY SUPPORTIVE THERAPY, 2018-2030 (USD MILLION)
TABLE 274. EGYPT HUNTER SYNDROME TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 275. EGYPT HUNTER SYNDROME TREATMENT MARKET SIZE, BY PATIENT AGE GROUP, 2018-2030 (USD MILLION)
TABLE 276. EGYPT HUNTER SYNDROME TREATMENT MARKET SIZE, BY ADULT, 2018-2030 (USD MILLION)
TABLE 277. EGYPT HUNTER SYNDROME TREATMENT MARKET SIZE, BY PEDIATRIC, 2018-2030 (USD MILLION)
TABLE 278. EGYPT HUNTER SYNDROME TREATMENT MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 279. TURKEY HUNTER SYNDROME TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
TABLE 280. TURKEY HUNTER SYNDROME TREATMENT MARKET SIZE, BY ENZYME REPLACEMENT THERAPY, 2018-2030 (USD MILLION)
TABLE 281. TURKEY HUNTER SYNDROME TREATMENT MARKET SIZE, BY GENE THERAPY, 2018-2030 (USD MILLION)
TABLE 282. TURKEY HUNTER SYNDROME TREATMENT MARKET SIZE, BY HEMATOPOIETIC STEM CELL TRANSPLANT, 2018-2030 (USD MILLION)
TABLE 283. TURKEY HUNTER SYNDROME TREATMENT MARKET SIZE, BY SUPPORTIVE THERAPY, 2018-2030 (USD MILLION)
TABLE 284. TURKEY HUNTER SYNDROME TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 285. TURKEY HUNTER SYNDROME TREATMENT MARKET SIZE, BY PATIENT AGE GROUP, 2018-2030 (USD MILLION)
TABLE 286. TURKEY HUNTER SYNDROME TREATMENT MARKET SIZE, BY ADULT, 2018-2030 (USD MILLION)
TABLE 287. TURKEY HUNTER SYNDROME TREATMENT MARKET SIZE, BY PEDIATRIC, 2018-2030 (USD MILLION)
TABLE 288. TURKEY HUNTER SYNDROME TREATMENT MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 289. ISRAEL HUNTER SYNDROME TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
TABLE 290. ISRAEL HUNTER SYNDROME TREATMENT MARKET SIZE, BY ENZYME REPLACEMENT THERAPY, 2018-2030 (USD MILLION)
TABLE 291. ISRAEL HUNTER SYNDROME TREATMENT MARKET SIZE, BY GENE THERAPY, 2018-2030 (USD MILLION)
TABLE 292. ISRAEL HUNTER SYNDROME TREATMENT MARKET SIZE, BY HEMATOPOIETIC STEM CELL TRANSPLANT, 2018-2030 (USD MILLION)
TABLE 293. ISRAEL HUNTER SYNDROME TREATMENT MARKET SIZE, BY SUPPORTIVE THERAPY, 2018-2030 (USD MILLION)
TABLE 294. ISRAEL HUNTER SYNDROME TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 295. ISRAEL HUNTER SYNDROME TREATMENT MARKET SIZE, BY PATIENT AGE GROUP, 2018-2030 (USD MILLION)
TABLE 296. ISRAEL HUNTER SYNDROME TREATMENT MARKET SIZE, BY ADULT, 2018-2030 (USD MILLION)
TABLE 297. ISRAEL HUNTER SYNDROME TREATMENT MARKET SIZE, BY PEDIATRIC, 2018-2030 (USD MILLION)
TABLE 298. ISRAEL HUNTER SYNDROME TREATMENT MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 299. NORWAY HUNTER SYNDROME TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
TABLE 300. NORWAY HUNTER SYNDROME TREATMENT MARKET SIZE, BY ENZYME REPLACEMENT THERAPY, 2018-2030 (USD MILLION)
TABLE 301. NORWAY HUNTER SYNDROME TREATMENT MARKET SIZE, BY GENE THERAPY, 2018-2030 (USD MILLION)
TABLE 302. NORWAY HUNTER SYNDROME TREATMENT MARKET SIZE, BY HEMATOPOIETIC STEM CELL TRANSPLANT, 2018-2030 (USD MILLION)
TABLE 303. NORWAY HUNTER SYNDROME TREATMENT MARKET SIZE, BY SUPPORTIVE THERAPY, 2018-2030 (USD MILLION)
TABLE 304. NORWAY HUNTER SYNDROME TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 305. NORWAY HUNTER SYNDROME TREATMENT MARKET SIZE, BY PATIENT AGE GROUP, 2018-2030 (USD MILLION)
TABLE 306. NORWAY HUNTER SYNDROME TREATMENT MARKET SIZE, BY ADULT, 2018-2030 (USD MILLION)
TABLE 307. NORWAY HUNTER SYNDROME TREATMENT MARKET SIZE, BY PEDIATRIC, 2018-2030 (USD MILLION)
TABLE 308. NORWAY HUNTER SYNDROME TREATMENT MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 309. POLAND HUNTER SYNDROME TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
TABLE 310. POLAND HUNTER SYNDROME TREATMENT MARKET SIZE, BY ENZYME REPLACEMENT THERAPY, 2018-2030 (USD MILLION)
TABLE 311. POLAND HUNTER SYNDROME TREATMENT MARKET SIZE, BY GENE THERAPY, 2018-2030 (USD MILLION)
TABLE 312. POLAND HUNTER SYNDROME TREATMENT MARKET SIZE, BY HEMATOPOIETIC STEM CELL TRAN

Companies Mentioned

The companies profiled in this Hunter Syndrome Treatment market report include:
  • Takeda Pharmaceutical Company Limited
  • Green Cross Corporation
  • Sanofi
  • JCR Pharmaceuticals
  • GC Pharma
  • Regenxbio
  • Denali Therapeutics

Methodology

Loading
LOADING...

Table Information

Report AttributeDetails
No. of Pages184
PublishedMay 2025
Forecast Period2025 - 2030
Estimated Market Value ( USD ) in 2025 $ 1.27 Billion
Forecasted Market Value ( USD ) by 2030 $ 1.88 Billion
Compound Annual Growth Rate8.1%
Regions CoveredGlobal
No. of Companies Mentioned8

Related Topics

Related Reports

Hunter Syndrome Treatment Market Size, Share & Trends Analysis Report by Type (Enzyme Replacement Therapy, Hematopoietic Stem Cell Transplant), Route Of Administration, End-use, Region, and Segment Forecasts, 2025-2030 - Product Image

Hunter Syndrome Treatment Market Size, Share & Trends Analysis Report by Type (Enzyme Replacement Therapy, Hematopoietic Stem Cell Transplant), Route Of Administration, End-use, Region, and Segment Forecasts, 2025-2030

  • Report
  • 100 Pages
  • Global
From
Hunter Syndrome Treatment - Global Strategic Business Report - Product Image

Hunter Syndrome Treatment - Global Strategic Business Report

  • Report
  • 94 Pages
  • Global
From
Hunter Syndrome Treatment Market - Global Industry Size, Share, Trends, Opportunity, and Forecast, 2020-2030F - Product Image

Hunter Syndrome Treatment Market - Global Industry Size, Share, Trends, Opportunity, and Forecast, 2020-2030F

  • Report
  • 185 Pages
  • Global
From
Hunter Syndrome Treatment Market Report and Forecast 2024-2032 - Product Image

Hunter Syndrome Treatment Market Report and Forecast 2024-2032

  • Report
  • 250 Pages
  • Global
From
Lysosomal Storage Diseases Market by Disease Type, Treatment Type, Therapeutic Application, End-User - Global Forecast to 2030 - Product Image

Lysosomal Storage Diseases Market by Disease Type, Treatment Type, Therapeutic Application, End-User - Global Forecast to 2030

  • Report
  • 198 Pages
  • Global
From

About the Mucopolysaccharidosis Drug Market

Mucopolysaccharidosis (MPS) is a group of rare, inherited metabolic disorders caused by the deficiency of lysosomal enzymes. These enzymes are responsible for breaking down complex sugars called glycosaminoglycans (GAGs). Without these enzymes, GAGs accumulate in the body, leading to a wide range of symptoms, including skeletal deformities, organ enlargement, and cognitive impairment. Treatment for MPS is focused on managing symptoms and preventing further progression of the disease. Immune disorders drugs are used to treat MPS, including enzyme replacement therapy (ERT), substrate reduction therapy (SRT), and gene therapy. ERT involves the administration of a recombinant enzyme to replace the missing enzyme, while SRT works by reducing the production of GAGs. Gene therapy is a newer approach that involves the introduction of a healthy gene into the patient's cells to replace the defective gene. Companies in the MPS drug market include Sanofi, Shire, Pfizer, and Ultragenyx Pharmaceuticals. Sanofi is a French pharmaceutical company that produces Aldurazyme, an ERT drug for MPS I. Shire is a biopharmaceutical company that produces Elaprase, an ERT drug for MPS II. Pfizer is an American pharmaceutical company that produces Vimizim, an ERT drug for MPS IV. Ultragenyx Pharmaceuticals is a biopharmaceutical company that produces Mep Show Less Read more

Copyright © 2002-2025 Research and Markets. All Rights Reserved.